Hutchinson-Gilford progeria syndrome

Handbook of Clinical Neurology

Volumn 132, Issue , 2015, Pages 249-264

  Ullrich, Nicole J ^a   Gordon, Leslie B ^a,b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c The Progeria Research Foundation   (United States)

Author keywords

Aging; Atherosclerosis; Cerebrovascular; CVD; HGPS; Lamin; Laminopathy; Orphan disease; Progeria; Rare disease; Stroke

Indexed keywords

LAMIN A; LMNA PROTEIN, HUMAN;

ANIMAL; CARDIOVASCULAR DISEASE; COMPLICATION; DISEASE MANAGEMENT; GENETICS; HUMAN; MOUSE; MUTATION; PATHOLOGY; PHAKOMATOSIS; PROGERIA;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; HUMANS; LAMIN TYPE A; MICE; MUTATION; NEUROCUTANEOUS SYNDROMES; PROGERIA;

EID: 84961246867     PISSN: 00729752     EISSN: 22124152     Source Type: Book Series    
DOI: 10.1016/B978-0-444-62702-5.00018-4     Document Type: Chapter

References (92)

1. Badame A.J. Progeria. Arch Dermatol 1989, 125:540-544.
2. Baek J.H., Schmidt E., Viceconte N., et al. Expression of progerin in aging mouse brains reveals structural nuclear abnormalities without detectible significant alterations in gene expression, hippocampal stem cells or behavior. Hum Mol Genet 2015, 24:1305-1321.
3. Benson E.K., Lee S.W., Aaronson S.A. Role of progerin-induced telomere dysfunction in HGPS premature cellular senescence. J Cell Sci 2010, 123:2605-2612.
4. Blondel S., Jaskowiak A.L., Egesipe A.L., et al. Induced pluripotent stem cells reveal functional differences between drugs currently investigated in patients with Hutchinson-Gilford progeria syndrome. Stem Cells Transl Med 2014, 3:510-519.
5. Cao H., Hegele R.A. Lmna is mutated in hutchinson-gilford progeria (mim 176670) but not in wiedemann-rautenstrauch progeroid syndrome (mim 264090). J Hum Genet 2003, 48:271-274.
6. Cao K., Blair C.D., Faddah D.A., et al. Progerin and telomere dysfunction collaborate to trigger cellular senescence in normal human fibroblasts. J Clin Invest 2011, 121:2833-2844.
7. Cao K., Graziotto J.J., Blair C.D., et al. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci Transl Med 2011, 3. 89ra58.
8. Capell B.C., Collins F.S. Human laminopathies: nuclei gone genetically awry. Nat Rev Genet 2006, 7:940-952.
9. Capell B.C., Erdos M.R., Madigan J.P., et al. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2005, 102:12879-12884.
10. Capell B.C., Olive M., Erdos M.R., et al. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci U S A 2008, 105:15902-15907.
11. Cau P., Navarro C., Harhouri K., et al. Nuclear matrix, nuclear envelope and premature aging syndromes in a translational research perspective. Semin Cell Dev Biol 2014, 29:125-147.
12. Cenni V., Capanni C., Columbaro M., et al. Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria. Eur J Histochem 2011, 55. E36.
13. Cleveland R.H., Gordon L.B., Kleinman M.E., et al. A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome. Pediatr Radiol 2012, 42:1089-1098.
14. Coppedè F. The epidemiology of premature aging and associated comorbidities. Clin Interv Aging 2013, 8:1023-1032.
15. Cox A.D., Der C.J. Farnesyltransferase inhibitors: promises and realities. Curr Opin Pharmacol 2002, 2:388-393.
16. Cruickshank K., Riste L., Anderson S.G., et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation 2002, 106:2085-2090.
17. Dahl K.N., Kalinowski A., Pekkan K. Mechanobiology and the microcirculation: cellular nuclear and fluid mechanics. Microcirculation 2010, 17:179-191.
18. De Sandre-Giovannoli A., Levy N. Altered splicing in prelamin A-associated premature aging phenotypes. Prog Mol Subcell Biol 2006, 44:199-232.
19. De Sandre-Giovannoli A., Bernard R., Cau P., et al. Lamin A truncation in Hutchinson-Gilford progeria. Science 2003, 300:2055.
20. Driscoll M., Albanese J., Xiong Z., et al. Automated image analysis of nuclear shape: what can we learn from a prematurely aged cell?. Aging (Albany NY). 2012, 4:119-132.
21. Eriksson M., Brown W.T., Gordon L., et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003, 423:293-298.
22. Espada J., Varela I., Flores I., et al. Nuclear envelope defects cause stem cell dysfunction in premature-aging mice. J Cell Biol 2008, 181:27-35.
23. Fong L.G., Frost D., Meta M., et al. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 2006, 311:1621-1623.
24. Fong L.G., Ng J.K., Lammerding J., et al. Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest 2006, 116:743-752.
25. Furukawa K., Inagaki H., Hotta Y. Identification and cloning of an MRNA coding for a germ cell-specific A-type lamin in mice. Exp Cell Res 1994, 212:426-430.
26. Gerhard-Herman M., Smoot L.B., Wake N., et al. Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome. Hypertension 2012, 59:92-97.
27. Gilford H. Progeria: a form of senilism. Practitioner 1904, 73:188-217.
28. Glynn M.W., Glover T.W. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities which are reversed by farnesyltransferase inhibition. Hum Mol Genet 2005, 14:2959-2969.
29. Goldman R.D., Shumaker D.K., Erdos M.R., et al. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2004, 101:8963-8968.
30. Gordon L.B. PRF by the numbers. Progeria Research Foundation 2013, Available: http://www.progeriaresearch.org/prf-by-the-numbers.html (accessed November 27, 2014).
31. Gordon L., Brown W.T., Collins F.S. Hutchinson-Gilford progeria syndrome. GeneReviews® 2003, 1-15.
32. Gordon L.B., Harten I.A., Patti M.E., et al. Reduced adiponectin and HDL cholesterol without elevated C-reactive protein: clues to the biology of premature atherosclerosis in Hutchinson-Gilford progeria syndrome. J Pediatr 2005, 146:336-341.
33. Gordon L.B., Mccarten K.M., Giobbie-Hurder A., et al. Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics 2007, 120:824-833.
34. Gordon C.M., Gordon L.B., Snyder B.D., et al. Hutchinson-Gilford progeria is a skeletal dysplasia. J Bone Miner Res 2011, 26:1670-1679.
35. Gordon L.B., Kleinman M.E., Miller D.T., et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2012, 109:16666-16671.
36. Gordon L.B., Massaro J., D'Agostino R.B., et al. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation 2014, 130:27-34.
37. Haithcock E., Dayani Y., Neufeld E., et al. Age-related changes of nuclear architecture in Caenorhabditis elegans. Proc Natl Acad Sci U S A 2005, 102:16690-16695.
38. Halaschek-Wiener J., Brooks-Wilson A. Progeria of stem cells: stem cell exhaustion in Hutchinson-Gilford progeria syndrome. J Gerontol A Biol Sci Med Sci 2007, 62:3-8.
39. Hennekam R.C. Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A 2006, 140:2603-2624.
40. Hisama F.M., Lessel D., Leistritz D., et al. Coronary artery disease in a Werner syndrome-like form of progeria characterized by low levels of progerin A splice variant of lamin A. Am J Med Genet A 2011, 155A:3002-3006.
41. Hutchinson J. Congenital absence of hair and mammary glands with atrophic condition of the skin and its appendages in a boy whose mother had been almost wholly bald from alopecia areata from the age of six. Med Chir Trans 1886, 69:473-477.
42. Hutchinson J., Gilford H. On a condition of mixed premature and immature development. Med Chir Trans 1897, 80:2-42.
43. Ibrahim M., Sayin V., Akula M., et al. Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria. Science 2013, 340:1330-1333.
44. Jung H.J., Coffinier C., Choe Y., et al. Regulation of prelamin A but not lamin C by miR-9, a brain-specific microRNA. Proc Natl Acad Sci U S A 2012, 109:E423-E431.
45. Kilic F., Dalton M.B., Burrell S.K., et al. In vitro assay and characterization of the farnesylation-dependent prelamin A endoprotease. J Biol Chem 1997, 272:5298-5304.
46. Kole R., Krainer A.R., Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012, 11:125-140.
47. Kudlow B.A., Stanfel M.N., Burtner C.R., et al. Suppression of proliferative defects associated with processing-defective lamin A mutants by hTERT or inactivation of p53. Mol Biol Cell 2008, 19:5238-5248.
48. Liu Y., Rusinol A., Sinensky M., et al. DNA damage responses in progeroid syndromes arise from defective maturation of prelamin A. J Cell Sci 2006, 119:4644-4649.
49. Liu G.H., Barkho B.Z., Ruiz S., et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 2011, 472:221-225.
50. Liu G.H., Suzuki K., Qu J., et al. Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell 2011, 8:688-694.
51. Liu B., Ghosh S., Yang X., et al. Resveratrol rescues SIRT1-dependent adult stem cell decline and alleviates progeroid features in laminopathy-based progeria. Cell Metab 2012, 16:738-750.
52. Liu G.-H., Ding Z., Izpisua Belmonte J.C. Ipsc technology to study human aging and aging-related disorders. Curr Opin Cell Biol 2012, 24:765-774.
53. Machiels B.M., Zorenc A.H., Endert J.M., et al. An alternative splicing product of the lamin A/C gene lacks exon 10. J Biol Chem 1996, 271:9249-9253.
54. Marino G., Ugalde A.P., Fernandez A.F., et al. Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function. Proc Natl Acad Sci U S A 2010, 107:16268-16273.
55. McClintock D., Gordon L.B., Djabali K. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-lamin A G608G antibody. Proc Natl Acad Sci U S A 2006, 103:2154-2159.
56. McClintock D., Ratner D., Lokuge M., et al. The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. Plos One 2007, 2:1-9.
57. Merideth M.A., Gordon L., Clauss S., et al. Phenotype and course of Hutchinson-Gilford progeria syndrome. New Engl J Med 2008, 358:592-604.
58. Moulson C.L., Fong L.G., Gardner J.M., et al. Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes. Hum Mutat 2007, 28:882-889.
59. Musich P.R., Zou Y. Genomic instability and DNA damage responses in progeria arising from defective maturation of prelamin A. Aging (Albany NY) 2009, 1:28-37.
60. Nissan X., Blondel S., Navarro C., et al. Unique preservation of neural cells in Hutchinson-Gilford progeria syndrome is due to the expression of the neural-specific miR-9 microRNA. Cell Rep 2012, 2:1-9.
61. Olive M., Harten I., Mitchell R., et al. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol 2010, 30:2301-2309.
62. Osorio F.G., Navarro C.L., Cadinanos J., et al. Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med 2011, 3:106-107.
63. Pegoraro G., Kubben N., Wickert U., et al. Ageing-related chromatin defects through loss of the nurd complex. Nat Cell Biol 2009, 11:1261-1267.
64. Pesce K., Rothe M.J. The premature aging syndromes. Clin Dermatol 1996, 14:161-170.
65. Rankin J., Ellard S. The laminopathies: a clinical review. Clin Genet 2006, 70:261-274.
66. Reddel C.J., Weiss A.S. Lamin a expression levels are unperturbed at the normal and mutant alleles but display partial splice site selection in hutchinson-gilford progeria syndrome. J Med Genet 2004, 41:715-717.
67. Reichel W., Garcia-Bunuel R. Pathologic findings in progeria: myocardial fibrosis and lipofuscin pigment. Am J Clin Path 1970, 53:243-253.
68. Rork J.F., Huang J.T., Gordon L.B., et al. Initial cutaneous manifestations of Hutchinson-Gilford progeria syndrome. Pediatr Dermatol 2014, 31:196-202.
69. Rosengardten Y., Mckenna T., Grochova D., et al. Stem cell depletion in Hutchinson-Gilford progeria syndrome. Aging Cell 2011, 10:1011-1020.
70. Sagelius H., Rosengardten Y., Schmidt E.S., et al. Reversible phenotype in a mouse model of Hutchinson-Gilford progeria syndrome. J Med Genet 2008, 45:794-801.
71. Scaffidi P., Misteli T. Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 2005, 11:440-445.
72. Scaffidi P., Misteli T. Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing. Nat Cell Biol 2008, 10:452-459.
73. Schmidt E., Nilsson O., Koskela A., et al. Expression of the Hutchinson-Gilford progeria mutation during osteoblast development results in loss of osteocytes irregular mineralization and poor biomechanical properties. J Biol Chem 2012, 287:33512-33522.
74. Shumaker D., Kuczmarski E., Goldman R. The nucleoskeleton: lamins and actin are major players in essential nuclear functions. Curr Opin Cell Biol 2003, 15:358-366.
75. Silvera V.M., Gordon L.B., Orbach D.B., et al. Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome. Am J Neuroradiol 2013, 34:1091-1097.
76. Sinensky M., Fantle K., Trujillo M., et al. The processing pathway of prelamin A. J Cell Sci 1994, 107:61-67.
77. Snow C.J., Dar A., Dutta A., et al. Defective nuclear import of Tpr in progeria reflects the Ran sensitivity of large cargo transport. J Cell Biol 2013, 201:541-557.
78. Stehbens W., Delahunt B., Shozawa T., et al. Smooth muscle cell depletion and collagen types in progeric arteries. Cardiovasc Pathol 2001, 10:133-136.
79. Tilli C.M., Ramaekers F.C., Broers J.L., et al. Lamin expression in normal human skin actinic keratosis squamous cell carcinoma and basal cell carcinoma. Br J Dermatol 2003, 148:102-109.
80. Tsze D.S., Valente J.H. Pediatric stroke: a review. Emerg Med Int 2011, 2011:734506.
81. Ugalde A.P., Ramsay A.J., De La Rosa J., et al. Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53. EMBO J 2011, 30:2219-2232.
82. Ullrich N.J., Silvera V.M., Campbell S.E., et al. Craniofacial abnormalities in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol 2012, 33:1512-1518.
83. Ullrich N.J., Kieran M.W., Miller D.T., et al. Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. Neurology 2013, 81:427-430.
84. Varela I., Cadinanos J., Pendas A.M., et al. Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature 2005, 437:564-568.
85. Varela I., Pereira S., Ugalde A.P., et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med 2008, 14:767-772.
86. Varga R., Eriksson M., Erdos M.R., et al. Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2006, 103:3250-3255.
87. Weber K., Plessmann U., Traub P. Maturation of nuclear lamin A involves a specific carboxy-terminal trimming which removes the polyisoprenylation site from the precursor; implications for the structure of the nuclear lamina. Febs Lett 1989, 257:411-414.
88. Wenzel V., Roedl D., Gabriel D., et al. Naive adult stem cells from patients with Hutchinson-Gilford progeria syndrome express low levels of progerin in vivo. Biol Open 2012, 1:516-526.
89. Wuyts W., Biervliet M., Reyniers E., et al. Somatic and gonadal mosaicism in Hutchinson-Gilford progeria. Am J Med Genet A 2005, 135:66-68.
90. Yang S.H., Bergo M.O., Toth J.I., et al. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci U S A 2005, 102:10291-10296.
91. Zhang J., Lian Q., Zhu G., et al. A human Ipsc model of Hutchinson Gilford progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 2011, 8:31-45.
92. Zhang H., Kieckhaefer J.E., Cao K. Mouse models of laminopathies. Aging Cell 2013, 12:2-10.